impact factor
logo
 

Full Papers

 

Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis


1, 2, 3, 4, 5, 6, 7, 8

 

  1. Department of Rheumatology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. talieviatar@gmail.com
  2. Department of Rheumatology, Carmel Medical Center, Haifa, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
  3. Sackler Faculty of Medicine, Tel Aviv University, and Rheumatology Unit, The Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer, Ramat Gan, Israel.
  4. Rheumatology Unit, Barzilai Medical Center, Ashkelon, Israel.
  5. The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, and B. Shine Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel.
  6. Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel.
  7. Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel.
  8. Department of Rheumatology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

CER14090
Full Papers

purchase article

PMID: 33427613 [PubMed]

Received: 02/10/2020
Accepted : 01/12/2020
In Press: 07/01/2021

Abstract

OBJECTIVES:
To prospectively study real-world efficacy and safety of secukinumab in psoriatic arthritis (PsA) patients from the Israeli registry of inflammatory diseases.
METHODS:
PsA patients fulfilling the CASPAR criteria were included in the analysis from 2010 to 2019. The primary endpoint was secukinumab drug retention compared to other TNF-α inhibitors (TNFi). Bivariate and multivariate analyses were made by Cox regression analysis. Drug retention according to treatment line was examined with Kaplan-Meier curves.
RESULTS:
Included were 404 PsA patients who had 709 treatment courses during the study period. Ninety patients had been treated with secukinumab (22%). The secukinumab-treated patients were significantly older and their disease duration was longer. Secukinumab was less likely to be the first line of treatment compared to TNFi. Secukinumab had a drug retention comparable to TNFi, and a better drug retention than TNFi among biologic-experienced patients. Neither methotrexate combination nor body mass index affected the inefficacy event rate. Secukinumab had a similar rate of adverse events as TNFi.
CONCLUSIONS:
This multicentre real-world study demonstrated that secukinumab had a drug retention comparable to TNFi. Secukinumab had a better drug retention than TNFi among biologic-experienced patients. IL-17 inhibition is an effective mechanism of action to treat PsA in real life.

Rheumatology Article

Rheumatology Addendum